Applying Pharmacometabolomics to Assess Large-Molecule Drug Effects in Human Placental Slices
Background
This project investigates how therapeutic antibodies, such as trastuzumab, interact with the human placenta during pregnancy. While these biologic medicines are increasingly prescribed to women of reproductive age, their effects on placental function and fetal safety remain insufficiently understood.
Tool:
To characterize the metabolic response of human placental tissue to the therapeutic monoclonal antibody Trastuzumab, using ex vivo placental slices combined with LC–HRMS pharmacometabolomics (PMx).
Aim
Using human placental tissue models combined with advanced metabolomics technologies, this study aims to detect subtle functional changes in placental metabolism that may not be visible through traditional genetic or molecular analyses. By focusing on metabolic pathways related to inflammation, oxidative stress, and energy balance, the project provides a systems-level view of how the placenta responds to antibody exposure.
Innovative/Influence
The innovative aspect of this work lies in applying metabolomics to placental research on biologic therapies, offering a new way to assess drug safety at the maternal–fetal interface. The findings are expected to contribute to improved risk assessment of medication use during pregnancy and to support safer, evidence-based treatment decisions for pregnant women.